04.30.24 -- 2024: The Year Of Development In Cell Therapy

Application scientist, Dr. Jorge Escobar Ivirico, explains and underscores the key differences with the production of exosomes from other cellular therapies.

Compare and contrast the pros and cons of several cleanroom design and construction methods to determine the most suitable approach for your specific project.

Creating a site-centric partnership between a pharmaceutical/biopharmaceutical sponsor and a clinical trial site can ease personnel and patient burdens, driving high-quality data collection and documentation.

While RA presents a substantial global health challenge, see how evolving therapies and research efforts offer hope for improved outcomes and better management of this debilitating condition.

Learn about a system that uses a gentle elutriation process to give manufacturers a cleaner cell population to begin cell therapy production processes such as CAR T.

Targeted metabolomics-based PAT allows for metabolic profiling of the T-cells throughout the cell therapy manufacturing process through spent media analysis.

Oncology clinical trials pose unique challenges. Dive into five key reasons behind the intricacies of oncology trials, from recruitment hurdles to data volume and efficacy endpoints.

By increasing recombinant AAV titers, this AAV enhancer can help reduce upstream manufacturing costs and lower the cost per therapeutic dose.

Find out how a multi-product cell therapy manufacturer chose the best cleanroom spaces for their work producing clinical grade products safely and efficiently.

In this exclusive interview, Dr. Quentin Bazot, Head of Innovation and Development from ABL, shares insights into the impact that a new photometer is having on ABL's AAV process development workflow.